MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION
Pentafluorophenylammonium triflate: A Mild, Efficient and Reusable Catalyst for the Synthesis of 2-Arylbenzothiazole and 2-Arylbenzothiazoline Derivatives in a Green Chemical Approach
作者:Arup Datta
DOI:10.13005/ojc/370112
日期:2021.2.28
simple and environmentally benign effective synthesis of 2-substituted benzothiazole and benzothiazoline derivatives are described in presence of PFPAT (pentafluorophenylammonium triflate) catalyst in water successfully. A series of benzothiazole derivative were synthesized by the reaction between 2-aminothiophenol and various aldehydes in good yields. Recyclability of the catalyst is observed for four
SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
申请人:Japan Tobacco Inc.
公开号:US20190300490A1
公开(公告)日:2019-10-03
The present invention relates to saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds, or pharmaceutically acceptable salts thereof, having RORγ antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula [I] or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided:
wherein each substituent is defined as defined in the description.
Pentafluorophenylammonium triflate-CuCl2: A mild, efficient and reusable heterogeneous catalyst system for facile synthesis of 4(3H)-quinazolinones under solvent-free conditions
recyclable heterogeneous catalyst for the synthesis of 4(3H)-quinazolinones by cyclocondensationreaction of 2-aminobenzamide with aryl aldehydes in the presence of CuCl2 as co-catalyst in good to excellent yields under solvent-free conditions. The present methodology offers several advantages, such as simple procedure with an easy work-up, high yields, short reaction times, and the absence of any volatile
DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF
申请人:JAPAN TOBACCO INC.
公开号:US20160194290A1
公开(公告)日:2016-07-07
A compound of Formula [I] or a pharmaceutically acceptable salt thereof:
wherein each symbol is defined as in the specification.
化合物的结构式[I]或其药用盐:其中每个符号的定义如规范中所述。
4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
申请人:Japan Tobacco Inc.
公开号:US20190300488A1
公开(公告)日:2019-10-03
The present invention relates to 4-methyldihydropyrimidinone compounds, or pharmaceutically acceptable salts thereof, having RORγ antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula (1) or (2) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided.